EBR/SEQUA (EBR/SEQUA)

Euronext Brussels: EBR/SEQUA · EUR

€0.61

+0.00 (0.0%)· Recorded snapshot

Market cap	43.6M
Net income (ttm)	-51.9M
EPS (ttm)	-€1.11
Shares out	71.3M
Volume	0
Beta	-0.30

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -51.9M
EPS (ttm): -€1.11
Market cap: 43.6M

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 13:30 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC-448.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All EBR/SEQUA indicators

Market & fundamental data

Available fields

148

Groups with data

Currency

EUR

Showing 148 of 148 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	EUR
Country	Belgium
Country code	BE
Earnings date	2026-09-14
Employees	48
Employees change	-14
Employees growth	-22.58%
Enterprise value	EUR 77.6M
Exchange	Euronext Brussels
Financial currency	EUR
Financial report date	2025-06-30
First seen	2026-05-10
Fiscal year end	December
Founded	2006
Industry	Medical Devices
Is primary listing	Yes
ISIN number	BE0974340722
Last earnings date	2026-04-28
Last refreshed	2026-10-29
Market cap	EUR 43.6M
Price	EUR 0.61
Price currency	EUR
Sector	Healthcare
SIC code	3841
Stock price date	2026-10-28
Symbol	ebr/SEQUA
Website	https://www.sequanamedical.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-181.4%
FCF / EV yield	-22.79%
FCF yield	-40.62%
Sector forward P/E	22.86x
Sector P/E	29.5x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	EUR -1.1M
ROA	-88.4%
ROA (5Y)	-100.75%
ROCE	47.72%
ROIC	-448.47%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth	-85.19%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	EUR -66,219
Depreciation and amortization	EUR 735,195
EBIT	EUR -17.9M
EBITDA	EUR -17.2M
EPS	EUR -1.11
FCF per share	EUR -0.25
Financing cash flow	EUR 20.9M
Free cash flow	EUR -17.7M
Free cash flow minus SBC	EUR -17.9M
Gross profit	EUR -355
Income taxes	EUR 260,904
Investing cash flow	EUR -70,923
Net borrowing	EUR 18M
Net cash flow	EUR 3.2M
Net income	EUR -51.9M
Operating cash flow minus SBC	EUR -17.8M
Operating income	EUR -17.9M
Stock-based compensation	EUR 187,164

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-32.69
Book value per share	EUR -0.68
Interest coverage	-1.65
Long-term assets	EUR 4M
Long-term liabilities	EUR 1.6M
Net cash (debt)	EUR -34.1M
Net cash / market cap	-78.26%
Piotroski F-Score	1
Property, plant and equipment	EUR 1.9M
Shareholders' equity	EUR -39.2M
Tangible book value	EUR -39.2M
Tangible book value per share	EUR -0.68
Total assets	EUR 14.6M
Total cash	EUR 7.3M
Total debt	EUR 41.4M
Total liabilities	EUR 53.7M
WACC	11.46%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	EUR 10.6M
Current liabilities	EUR 52.2M
Current ratio	0.2
Inventory turnover	0
Net working capital	EUR -8.2M
Quick ratio	0.15
Working capital	EUR -41.6M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-54.42%
Shareholder yield	-54.42%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	EUR 0.60
1D price change	0%
1Y price change	-17.21%
1Y return CAGR	-17.22%
1Y total return	-17.21%
20-day SMA	EUR 0.61
200-day SMA	EUR 0.59
3Y price change	-77.86%
3Y return CAGR	-39.5%
3Y total return	-77.86%
50-day SMA	EUR 0.61
50-day SMA vs 200-day SMA	50over200
52-week high	EUR 0.87
52-week high date	2025-11-25
52-week low	EUR 0.46
52-week low date	2026-03-30
5Y price change	-91.56%
5Y return CAGR	-39.01%
5Y total return	-91.56%
6M price change	-3.02%
6M total return	-3.02%
All-time high	EUR 12.40
All-time high date	2021-01-04
All-time low	EUR 0.46
All-time low date	2026-03-30
Average true range (ATR)	EUR 0.00
Average volume	0
Beta (1Y)	0.59
Beta (2Y)	2.27
Beta (5Y)	-0.3
Change from 52-week high	-29.36%
Change from 52-week low	32.83%
Change from all-time high	-95.07%
Change from all-time low	32.83%
Change from open	-8.67%
Day's gap	9.49%
High price	EUR 0.67
Low price	EUR 0.56
Monthly RSI	38.6
Open price	EUR 0.67
Position in 52-week range	46.79%
Previous close	EUR 0.61
Price vs 150-day SMA	2.14%
Price vs 20-day SMA	0%
Price vs 200-day SMA	3.98%
Price vs 50-day SMA	0%
Relative volume	4.32
RSI	68.92
Sharpe ratio	-0.1
Sharpe ratio (3Y)	0.11
Sharpe ratio (5Y)	-0.04
Sortino ratio	-0.04
Sortino ratio (3Y)	0.32
Sortino ratio (5Y)	-0.02
Volume	0
Weekly RSI	46.93
YTD price change	-3.63%
YTD total return	-3.63%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	50.7M
Shares change (QoQ)	27.4%
Shares held by insiders	6.46%
Shares held by institutions	12.37%
Shares outstanding	71.3M

Deeper analysis on EBR/SEQUA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this EBR/SEQUA report

Is a complete EBR/SEQUA research report available?

No complete published report is available for ebr/SEQUA (EBR/SEQUA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

EBR/SEQUA (EBR/SEQUA)

Price

Financial snapshot

Fair-value bridge

Latest news · EBR/SEQUA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All EBR/SEQUA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on EBR/SEQUA

Frequently asked questions